<DOC>
	<DOCNO>NCT00006101</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development cancer . The use eflornithine may effective way prevent development prostate cancer . PURPOSE : Randomized phase II trial determine effectiveness eflornithine prevent prostate cancer patient high risk develop disease .</brief_summary>
	<brief_title>Eflornithine Treating Patients At High Risk Developing Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare level polyamines ( putrescine , spermidine , spermine ) progression-related gene prostate tissue patient high genetic risk prostate cancer treat eflornithine ( DFMO ) v placebo . - Determine side effect DFMO compare biological effect prostate gland patient . OUTLINE : This randomize , double-blind , placebo-controlled study . Patients stratify accord age ( 35 60 v 61 70 ) presence localize cancer ( yes v ) . All patient receive oral placebo daily 4 week . Patients compliant take placebo 5-7 day week randomize one two arm . - Arm I : Patients receive oral placebo daily . - Arm II : Patients receive high-dose oral eflornithine ( DFMO ) daily . Treatment continue 1 year absence unacceptable toxicity . PROJECTED ACCRUAL : A total 100 patient ( 50 per arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Unaffected brother firstdegree cousin young ( age 70 ) prostate cancer proband family history ( two firstdegree relative ) prostate cancer No prior nonlocalized prostate cancer previously diagnose premalignant prostate disease PATIENT CHARACTERISTICS : Age : 35 70 Performance status : SWOG 01 OR Karnofsky 70100 % Life expectancy : At least 5 year Hematopoietic : Hematocrit least 35 % WBC least 4,000/mm^3 normal differential Platelet count least 100,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL SGOT SGPT less 2 time normal Renal : Creatinine le 1.5 mg/dL Less 1+ protein , 03 cast , 05 WBCs RBCs urine Gastrointestinal : No medically mandate special diet would preclude compliance study participation No document symptomatic gastric duodenal ulcer disease within past year Other : No severe metabolic disorder lifethreatening acute chronic disease No invasive cancer within past 5 year except nonmelanoma skin cancer No predisposition difficulty wound heal repair PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No concurrent chemotherapy Endocrine therapy : At least 3 month since prior finasteride Radiotherapy : No prior radiotherapy pelvic area No concurrent xrays Surgery : Not specify Other : At least 3 month since prior chemoprevention agent No aspirin aspirincontaining product within 10 day prior study biopsy No concurrent anticoagulant</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>stage I prostate cancer</keyword>
</DOC>